Biotech Stock Mailbag: Gleaming the Cubist
Next up, an email from Fareed H., who writes, "We know you don't like Cell Therapeutics, but the company has to be worth something. What's your price target on the stock?"
I did some quick calculations and came up with a fair value for Cell Therapeutics in the range of 20 cents to 30 cents a share.
This valuation takes into account the lowered debt level and assumes the cancer drug pixantrone is approved (risk adjusted to 85%) and does $100 million in peak sales. I give no value to Opaxio because I don't believe that drug is approvable ever, nor did I give the company any credit for whatever else sits in the pipeline.Obviously, the value of Cell Therapeutics rises if pixantrone does better or if something else from the company's pipeline is a success. At this point, I believe assuming $100 million in pixantrone sales is a generous forecast.
Jonathan L. isn't impressed with my biotech stocks picks from last week or the performance of my model portfolio. "Your portfolio was up only 21%, what a joke. I can close my eyes throw a dart and beat 21%, and you're the one with a platform to give stock advice. What a joke. The only thing you're good at is destroying the wealth of everyday Americans after the worst economic disaster since the Depression. What you do is no less than stealing food off the tables of hard working [sic] American investors. What a joke. Let me guess next time Cell Therapeutics or Hemispherx Biopharma (HEB) come out with good news you're going to bash them to get the stock price down, so you're [sic] hedge buddies can pick up cheap shares by costing real Americans thousands if not millions. I bet you've never worked a day in your life. You look like a [bleeping] worm. I just had to throw in that last comment. Have a nice day."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV